Patents by Inventor Markus Mägerlein

Markus Mägerlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10653625
    Abstract: A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 19, 2020
    Assignee: Abbvie Deutschland GmbH & Co. KG
    Inventors: Jörg Rosenberg, Markus Mägerlein, Bernd Liepold, Jörg Breitenbach
  • Patent number: 9402909
    Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 2, 2016
    Assignee: Abbvie Deutschland GmbH & Co KG
    Inventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Henzel, Thomas K. Kessler
  • Patent number: 9174944
    Abstract: This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: November 3, 2015
    Assignee: ABBVIE INC.
    Inventors: Yuchuan Gong, Geoff G. Zhang, Matthias Degenhardt, Markus Maegerlein
  • Patent number: 9149431
    Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 6, 2015
    Assignees: Abbvie Deutschland GmbH & Co KG, Barrier Therapeutics, Inc.
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
  • Patent number: 9060936
    Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: June 23, 2015
    Assignee: Abbvie Deutschland GmbH & Co. KG
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
  • Patent number: 9004752
    Abstract: A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 14, 2015
    Assignees: Abbvie, Inc., Abbvie Deutschland GmbH & Co KG, Wisconsin Alumni Research Foundation
    Inventors: Geoff G. Zhang, Lian Yu, Jing Tao, Ye Sun, Markus Maegerlein
  • Publication number: 20140200278
    Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 17, 2014
    Applicant: Abbvie Deutschland GmbH & Co. KG
    Inventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Henzel, Thomas K. Kessler
  • Publication number: 20140005204
    Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Ht, represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.
    Type: Application
    Filed: June 21, 2013
    Publication date: January 2, 2014
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
  • Publication number: 20130199313
    Abstract: A method for evaluating the solubility of a crystalline substance in a polymer comprises a) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration; b) annealing the sample at a constant temperature Ta for a period of time; c) heating the annealed sample while recording the heat flux over time by DSC; d) identifying a DSC dissolution endotherm in the recorded heat flux, if any; e) considering the crystalline substance concentration as a concentration above the crystalline substance solubility in the polymer at temperature Ta when there is a DSC dissolution endotherm identified, and considering the crystalline substance concentration as a concentration less than or equal to the crystalline substance solubility in the polymer at temperature Ta when there is no DSC dissolution endotherm identified.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 8, 2013
    Applicants: Abbott GmbH & Co, KGW, Boards of Regents of the University of Wisconsin System, AbbVie Inc.
    Inventors: Geoff G. Zhang, Lian Yu, Jing Tao, Markus Maegerlein
  • Patent number: 8486456
    Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: July 16, 2013
    Assignee: Abbott GmbH & Co., KG
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
  • Publication number: 20110311595
    Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 22, 2011
    Applicant: Abbott GmbH & Co. KG
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
  • Publication number: 20110261857
    Abstract: A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices.
    Type: Application
    Filed: April 29, 2009
    Publication date: October 27, 2011
    Applicant: Abbott GmbH & Co. KG
    Inventors: Geoff G. Zhang, Lian Yu, Jing Tao, Ye Sun, Markus Maegerlein
  • Publication number: 20110182891
    Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.
    Type: Application
    Filed: June 30, 2009
    Publication date: July 28, 2011
    Applicant: Abbott GmbH & Co., KG
    Inventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Packhäuser, Thomas K. Kessler
  • Publication number: 20100297223
    Abstract: A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4.
    Type: Application
    Filed: December 18, 2008
    Publication date: November 25, 2010
    Applicant: ABBOTT GMBH & CO. KG
    Inventors: Jörg Rosenberg, Markus Mägerlein, Jörg Breitenbach, Tina Jung, Ulrich Westedt
  • Publication number: 20090220596
    Abstract: A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.
    Type: Application
    Filed: June 22, 2006
    Publication date: September 3, 2009
    Applicant: Abbott GmbH & Co. KG
    Inventors: Jörg Rosenberg, Markus Mäegerlein, Jörg Breitenbach
  • Publication number: 20090214656
    Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.
    Type: Application
    Filed: August 8, 2006
    Publication date: August 27, 2009
    Applicants: ABBOTT GMBH & CO. KG, BARRIER THERAPEUTICS
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
  • Publication number: 20090028938
    Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.
    Type: Application
    Filed: August 8, 2006
    Publication date: January 29, 2009
    Applicant: Abbott GmbH & Co. KG
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
  • Publication number: 20070190142
    Abstract: A dosage form and method for the delivery of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, tampering, crushing, or grinding, and providing an initial burst of release of drug followed by a prolonged period of controllable drug release.
    Type: Application
    Filed: January 22, 2007
    Publication date: August 16, 2007
    Applicant: Abbott GmbH & Co. KG
    Inventors: Jorg BREITENBACH, Ute Lander, Jorg Rosenberg, Markus Maegerlein, Gerd Woehrle
  • Publication number: 20030153608
    Abstract: Stable pharmaceutical preparations, comprising torasemide in noncrystalline form.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 14, 2003
    Inventors: Markus Maegerlein, Thomas Hantke, Jorg Breitenbach, Jorg Rosenberg
  • Publication number: 20030119882
    Abstract: The present invention relates to a solid pharmaceutical composition, comprising
    Type: Application
    Filed: October 17, 2002
    Publication date: June 26, 2003
    Inventor: Markus Maegerlein